Hospital Professional News met with Owen McKeon, Country Manager for Mylan and chair of Medicines for Ireland, to discuss biosimilars, Brexit and the new Falsified Medicines Directive
The pharmaceutical industry in Ireland is facing a perfect storm in the first few months of 2019. Uncertainty created by Brexit, the new regulations from the Falsified Medicines Directive and higher HPRA fees have all combined to make manufacturing conditions more challenging.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
